隴神戎發(300534.SZ):保健食品黃芪當歸膠囊獲得泰國保健食品註冊證書
格隆匯 3 月 31日丨隴神戎發(300534.SZ)公佈,近日,公司全資子公司甘肅新絲路產業投資有限公司收到通知,獲悉公司擁有的保健食品黃芪當歸膠囊獲得泰國保健食品註冊證書。
黃芪當歸膠囊主要針對長期在輻射環境工作和接觸電腦的人羣,對輻射危害有輔助保護功能,其三大主要功能為抗輻射、抗氧化、提高免疫力。
此次公司保健食品黃芪當歸膠囊獲得泰國保健食品註冊證書,標誌着公司獲得正式出口至泰國市場銷售上述產品的資格,將對公司拓展海外市場產品銷售帶來積極影響,公司後續將積極推動此次獲得註冊證書產品在泰國上市銷售的準備工作。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.